Global Cord Blood Corp (CORBF)
OTCMKTS: CORBF · Delayed Price · USD
1.250
0.00 (0.00%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Global Cord Blood Revenue
In the fiscal year ending March 31, 2022, Global Cord Blood had annual revenue of $194.26M with 10.06% growth. Revenue in the quarter ending March 31, 2022 was $46.44M with 0.92% year-over-year growth.
Revenue (ttm)
$194.26M
Revenue Growth
+10.06%
P/S Ratio
0.86
Revenue / Employee
$161,613
Employees
1,202
Market Cap
167.39M USD
Revenue Chart
* The company reports in CNY currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2022 | 194.26M | 17.75M | 10.06% |
Mar 31, 2021 | 176.51M | 2.01M | 1.15% |
Mar 31, 2020 | 174.49M | 27.22M | 18.48% |
Mar 31, 2019 | 147.28M | -934.34K | -0.63% |
Mar 31, 2018 | 148.21M | 37.93M | 34.39% |
Mar 31, 2017 | 110.28M | 7.76M | 7.56% |
Mar 31, 2016 | 102.53M | -51.93K | -0.05% |
Mar 31, 2015 | 102.58M | 10.22M | 11.06% |
Mar 31, 2014 | 92.36M | 7.84M | 9.27% |
Mar 31, 2013 | 84.52M | 24.13M | 39.97% |
Mar 31, 2012 | 60.39M | 8.54M | 16.47% |
Mar 31, 2011 | 51.85M | 13.54M | 35.33% |
Mar 31, 2010 | 38.31M | 9.84M | 34.58% |
Mar 31, 2009 | 28.47M | -4.77M | -14.35% |
Mar 31, 2008 | 33.24M | 31.59M | 1,919.66% |
Mar 31, 2007 | 1.65M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
CORBF News
- 1 day ago - ROSEN, A RANKED AND LEADING FIRM, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - CO, CORBF - PRNewsWire
- 1 day ago - Global Cord Blood Corporation (CO) Investor Notice: Robbins LLP Reminds Stockholders of the Global Cord Blood Corporation Class Action - Business Wire
- 4 days ago - ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Global Cord Blood Corporation Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – CO, CORBF - Business Wire
- 11 months ago - NYSE to Commence Delisting Proceedings Against Global Cord Blood Corporation (CO) - Business Wire
- 1 year ago - GLOBAL CORD BLOOD CORPORATION ANNOUNCES FAILURE TO FILE INTERIM FINANCIALS - PRNewsWire
- 1 year ago - Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands - Business Wire
- 1 year ago - The Grand Court of the Cayman Islands Granted Blue Ocean's Application to Appoint Joint Provisional Liquidators for Global Cord Blood Corporation - Business Wire
- 1 year ago - Global Cord Blood Corporation Files Annual Report on Form 20-F - PRNewsWire